{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.4","upperLimit":"58","value":"31.4"},{"comment":"NA = OS upper limit was not reached (insufficient number of deaths by time of last disease assessment).","groupId":"OG001","lowerLimit":"19.2","upperLimit":"NA","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"OS is defined as the time from first day of study treatment to death due to any cause. Participants without documented death at the time of analysis are censored at the date of the last follow-up. OS was summarized by Kaplan-Meier (KM) methods. The data cutoff date was 19-FEB-2021.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 35 cycles (up to approximately 2 years).","id":"OG000","title":"Cohort A - Pembrolizumab 200 mg"},{"description":"Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants received pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 35 cycles (up to approximately 2 years).","id":"OG001","title":"Cohort B - Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}